SzeYuan(Grace) Yang is a distinguished pharmaceutical executive with over 26 years of strategic leadership experience, specializing in high-value therapeutic areas including oncology, chronic diseases, and innovative medicine. She possesses a proven track record of driving exponential corporate growth through expert execution of Mergers & Acquisitions, Business Development & Licensing (BD&L), and international market expansion across Taiwan and key Asian markets. Her comprehensive expertise spans the full product lifecycle, from initial clinical research and medical affairs to new product planning and full-scale commercialization, positioning her as the ideal strategic partner to drive innovative therapies from clinical development to commercial dominance across the Asia-Pacific region.  

TSH Biopharm (TW:8432) is focusing on chronic diseases and autoimmune conditions through innovative services and medicines.  Growth comes from NCE, TNCE, BLA, 505b2, NGS diagnosis, and innovation therapy.